Search

Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.

 

Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.

Read more

Strategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition

PRESS RELEASE
Strategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition

The Hague, Wednesday 18, November, 2020

The field of cell and gene therapy is one of the most…

Read more

EHA Kick-off Grants

The call for applications will close on October 1, 2024, at 15:00 (CEST).   Apply now

The EHA Kick-off Grant is a one-year grant intended to support basic and translational early career researchers in hematology.

Read more

Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients

Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.

Read more

SWG Educational Activities

2023 meetingsThe following EHA-SWG meetings took place in the past calendar year:

54th General Assembly of ERIC members at ELN Symposium 2023
Mannheim, Germany
April 18, 2023

ERIC/Brazilian CLL Group workshop on biomarkers in CLL
Brasilia, Brazil
May 25–26, 2023

55th General Assembly of ERIC members at…

Read more